Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Prostate cancer treatment and ten-year survival among group/staff HMO and fee-for-service Medicare patients.

Potosky AL, Merrill RM, Riley GF, Taplin SH, Barlow W, Fireman BH, Lubitz JD.

Health Serv Res. 1999 Jun;34(2):525-46.

2.

Impact of patient and provider characteristics on the treatment and outcomes of colorectal cancer.

Hodgson DC, Fuchs CS, Ayanian JZ.

J Natl Cancer Inst. 2001 Apr 4;93(7):501-15. Review.

PMID:
11287444
3.

Treatment disparities for disabled medicare beneficiaries with stage I non-small cell lung cancer.

Iezzoni LI, Ngo LH, Li D, Roetzheim RG, Drews RE, McCarthy EP.

Arch Phys Med Rehabil. 2008 Apr;89(4):595-601. doi: 10.1016/j.apmr.2007.09.042. Review.

PMID:
18373987
4.

Managed care and the delivery of primary care to the elderly and the chronically ill.

Wholey DR, Burns LR, Lavizzo-Mourey R.

Health Serv Res. 1998 Jun;33(2 Pt Ii):322-53. Review.

5.

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer.

Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL.

Ann Intern Med. 2008 Mar 18;148(6):435-48. Epub 2008 Feb 4. Review. Erratum in: Ann Intern Med. 2008 Jun 3;148(11):888.

PMID:
18252677
7.
8.

Review of studies that compare the quality of cardiovascular care in HMO versus non-HMO settings.

Seidman JJ, Bass EP, Rubin HR.

Med Care. 1998 Dec;36(12):1607-25. Review.

PMID:
9860052
9.

Development of an end-stage renal disease managed care demonstration.

Cooper BS, Eggers PW, Edington BM.

Adv Ren Replace Ther. 1997 Oct;4(4):332-9. Review.

PMID:
9356685
10.

Surveillance is not a viable and appropriate treatment option in the management of localized prostate cancer.

Hugosson J, Aus G, Norlén L.

Urol Clin North Am. 1996 Nov;23(4):557-73. Review.

PMID:
8948411
11.

Detection and treatment of prostate cancer: perspective of the urologist.

Olsson CA, Goluboff ET.

J Urol. 1994 Nov;152(5 Pt 2):1695-9. Review.

PMID:
7933229
13.

The Prostate Cancer Intervention Versus Observation Trial (PIVOT).

Wilt TJ, Brawer MK.

Oncology (Williston Park). 1997 Aug;11(8):1133-9; discussion 1139-40, 1143. Review.

14.

HMO use of diagnostic tests: a review of the evidence.

Chewnew M.

Med Care Res Rev. 1995 Jun;52(2):196-222. Review. No abstract available.

PMID:
10154560
15.

Problems and perspectives on the use of decision-analysis models for prostate cancer.

Simpson KN.

J Urol. 1994 Nov;152(5 Pt 2):1888-93. Review.

PMID:
7933245
16.

HMO data systems in population studies of access to care.

Fink R.

Health Serv Res. 1998 Aug;33(3 Pt 2):741-59; discussion 761-6. Review.

17.

Overuse and systems of care: a systematic review.

Keyhani S, Falk R, Howell EA, Bishop T, Korenstein D.

Med Care. 2013 Jun;51(6):503-8. doi: 10.1097/MLR.0b013e31828dbafe. Review.

18.

Prostate cancer: 11. Alternative approaches and the future of treatment.

Trachtenberg J, Crook J, Tannock IF.

CMAJ. 1999 Feb 23;160(4):528-34. Review. No abstract available.

19.

Hospital Stays in Medicare Advantage Plans Versus the Traditional Medicare Fee-for-Service Program, 2013: Statistical Brief #198.

Raetzman SO, Hines AL, Barrett ML, Karaca Z.

Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Feb-.
2015 Dec.

20.

Medicare Hospital Stays: Comparisons Between the Fee-for-Service Plan and Alternative Plans, 2006: Statistical Brief #66.

Friedman B, Jiang HJ, Russo CA.

Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Feb-.
2009 Jan.

Supplemental Content

Support Center